Orexo AB (publ) (ORX.ST)
SEK 20.8
(-5.24%)
SEK 20.8
(-5.24%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -109.5 Million SEK | 42.72% |
| 2022 | -214.2 Million SEK | 4.76% |
| 2021 | -224.9 Million SEK | -917.65% |
| 2020 | -22.1 Million SEK | -109.56% |
| 2019 | 231.2 Million SEK | 141.34% |
| 2018 | 95.8 Million SEK | 66.9% |
| 2017 | 57.4 Million SEK | 11.03% |
| 2016 | 51.7 Million SEK | 130.59% |
| 2015 | -168.98 Million SEK | -575.75% |
| 2014 | -25 Million SEK | 82.1% |
| 2013 | -139.68 Million SEK | -75.91% |
| 2012 | -79.41 Million SEK | 79.72% |
| 2011 | -391.5 Million SEK | -378.77% |
| 2010 | -81.77 Million SEK | 17.47% |
| 2009 | -99.08 Million SEK | 11.92% |
| 2008 | -112.49 Million SEK | 37.7% |
| 2007 | -180.56 Million SEK | -344.86% |
| 2006 | -40.59 Million SEK | 8.91% |
| 2005 | -44.56 Million SEK | -6730.95% |
| 2004 | 672 Thousand SEK | 124.75% |
| 2003 | 299 Thousand SEK | 424.56% |
| 2002 | 57 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -9 Million SEK | -800.0% |
| 2024 Q2 | -21 Million SEK | -133.33% |
| 2024 Q3 | -21.7 Million SEK | -3.33% |
| 2023 Q3 | -28.6 Million SEK | -120.0% |
| 2023 Q4 | -1 Million SEK | 96.5% |
| 2023 FY | -122.7 Million SEK | 42.72% |
| 2023 Q2 | -13 Million SEK | 78.08% |
| 2023 Q1 | -59.3 Million SEK | 41.46% |
| 2022 Q1 | -13.2 Million SEK | 79.41% |
| 2022 Q2 | -49.7 Million SEK | -276.52% |
| 2022 Q3 | -49.9 Million SEK | -0.4% |
| 2022 Q4 | -101.3 Million SEK | -103.01% |
| 2022 FY | -214.2 Million SEK | 4.76% |
| 2021 FY | -224.9 Million SEK | -917.65% |
| 2021 Q1 | -36.8 Million SEK | -234.55% |
| 2021 Q2 | -54 Million SEK | -46.74% |
| 2021 Q4 | -64.1 Million SEK | -8.64% |
| 2021 Q3 | -59 Million SEK | -9.26% |
| 2020 Q3 | -29.6 Million SEK | -122.56% |
| 2020 Q1 | 34 Million SEK | -52.45% |
| 2020 FY | -22.1 Million SEK | -109.56% |
| 2020 Q2 | -13.3 Million SEK | -139.12% |
| 2020 Q4 | -11 Million SEK | 62.84% |
| 2019 Q2 | 52.8 Million SEK | 4700.0% |
| 2019 Q3 | 105.9 Million SEK | 100.57% |
| 2019 Q4 | 71.5 Million SEK | -32.48% |
| 2019 FY | 231.2 Million SEK | 141.34% |
| 2019 Q1 | 1.1 Million SEK | -97.07% |
| 2018 Q3 | 34.6 Million SEK | -23.79% |
| 2018 FY | 95.8 Million SEK | 66.9% |
| 2018 Q2 | 45.4 Million SEK | 308.26% |
| 2018 Q4 | 37.6 Million SEK | 8.67% |
| 2018 Q1 | -21.8 Million SEK | -172.43% |
| 2017 Q3 | 40.9 Million SEK | 317.35% |
| 2017 Q2 | 9.8 Million SEK | 142.24% |
| 2017 Q1 | -23.2 Million SEK | -169.88% |
| 2017 FY | 57.4 Million SEK | 11.03% |
| 2017 Q4 | 30.1 Million SEK | -26.41% |
| 2016 FY | 51.7 Million SEK | 130.59% |
| 2016 Q3 | 43 Million SEK | 255.37% |
| 2016 Q2 | 12.1 Million SEK | 146.18% |
| 2016 Q1 | -26.2 Million SEK | 40.86% |
| 2016 Q4 | 33.2 Million SEK | -22.79% |
| 2015 FY | -168.98 Million SEK | -575.75% |
| 2015 Q1 | -8.1 Million SEK | -113.73% |
| 2015 Q2 | -77.3 Million SEK | -854.32% |
| 2015 Q3 | -39.4 Million SEK | 49.03% |
| 2015 Q4 | -44.3 Million SEK | -12.44% |
| 2014 Q2 | -38.4 Million SEK | -137.04% |
| 2014 Q4 | 58.99 Million SEK | 301.34% |
| 2014 FY | -25 Million SEK | 82.1% |
| 2014 Q3 | -29.3 Million SEK | 23.7% |
| 2014 Q1 | -16.2 Million SEK | 49.04% |
| 2013 Q1 | 30.2 Million SEK | 239.11% |
| 2013 Q2 | -112.7 Million SEK | -473.18% |
| 2013 Q4 | -31.78 Million SEK | -24.66% |
| 2013 Q3 | -25.5 Million SEK | 77.37% |
| 2013 FY | -139.68 Million SEK | -75.91% |
| 2012 FY | -79.41 Million SEK | 79.72% |
| 2012 Q4 | -21.71 Million SEK | 25.65% |
| 2012 Q2 | -14.4 Million SEK | -2.13% |
| 2012 Q3 | -29.2 Million SEK | -102.78% |
| 2012 Q1 | -14.1 Million SEK | 94.78% |
| 2011 FY | -391.5 Million SEK | -378.77% |
| 2011 Q4 | -269.97 Million SEK | -340.13% |
| 2011 Q3 | -61.34 Million SEK | -160.06% |
| 2011 Q2 | -23.58 Million SEK | 35.56% |
| 2011 Q1 | -36.6 Million SEK | -1434.83% |
| 2010 Q3 | -25.81 Million SEK | 19.39% |
| 2010 Q1 | -26.68 Million SEK | 53.95% |
| 2010 FY | -81.77 Million SEK | 17.47% |
| 2010 Q2 | -32.01 Million SEK | -19.97% |
| 2010 Q4 | 2.74 Million SEK | 110.62% |
| 2009 FY | -99.08 Million SEK | 11.92% |
| 2009 Q1 | 20.08 Million SEK | 223.43% |
| 2009 Q2 | -55.4 Million SEK | -375.83% |
| 2009 Q3 | -5.8 Million SEK | 89.51% |
| 2009 Q4 | -57.95 Million SEK | -897.73% |
| 2008 Q3 | -684 Thousand SEK | 0.0% |
| 2008 Q4 | -16.27 Million SEK | -2278.95% |
| 2008 FY | -112.49 Million SEK | 37.7% |
| 2007 FY | -180.56 Million SEK | -344.86% |
| 2006 FY | -40.59 Million SEK | 8.91% |
| 2005 FY | -44.56 Million SEK | -6730.95% |
| 2004 FY | 672 Thousand SEK | 124.75% |
| 2003 FY | 299 Thousand SEK | 424.56% |
| 2002 FY | 57 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AcuCort AB | -13.24 Million SEK | -726.477% |
| AlzeCure Pharma AB (publ) | -38.26 Million SEK | -186.185% |
| BioGaia AB (publ) | 440.9 Million SEK | 124.835% |
| Enzymatica AB (publ) | -48.06 Million SEK | -127.831% |
| Enorama Pharma AB (publ) | -41.83 Million SEK | -161.724% |
| Gabather AB (publ) | -9.47 Million SEK | -1055.795% |
| Klaria Pharma Holding AB (publ.) | -14.68 Million SEK | -645.913% |
| Moberg Pharma AB (publ) | -27.46 Million SEK | -298.718% |
| Nanexa AB (publ) | -76.62 Million SEK | -42.904% |
| Newbury Pharmaceuticals AB (publ) | -14.07 Million SEK | -677.809% |
| ODI Pharma AB | -1.34 Million SEK | -8061.653% |
| Probi AB (publ) | 11.32 Million SEK | 1067.314% |
| Swedencare AB (publ) | 173.2 Million SEK | 163.222% |
| Swedish Orphan Biovitrum AB (publ) | 4.65 Billion SEK | 102.352% |
| Toleranzia AB | -7.89 Million SEK | -1287.657% |
| Vivesto AB | -356.71 Million SEK | 69.304% |